The farnesyltransferase (FTase) inhibitor FTI-277 is highly eective at blocking oncogenic H-Ras but not KRas4B processing and signaling. While inhibition of processing and signaling of oncogenic K-Ras4B is more sensitive to the geranylgeranyltransferase I (GGTase I) inhibitor GGTI-286 than it is to FTI-277 in K-Ras4B-transformed NIH3T3 cells, the sensitivity of K-Ras as well as H-and N-Ras to the CAAX peptidomimetics in human tumor cell lines is not known. Here, we report that a panel of ®ve human carcinoma cell lines from pancreatic, pulmonary, and bladder origins all express H-, N-, and K-Ras, and their respective prenylation sensitivities to the FTase and GGTase I inhibitors is variable. In all of the cell lines investigated, the prenylation of N-Ras was highly sensitive to FTI-277, and in two of the cell lines, N-Ras showed slight sensitivity to GGTI-298, an analog of GGTI-286. Although the prenylation of H-Ras was also sensitive to FTI-277, complete inhibition of H-Ras processing even at high concentrations of FTI-277 and/or GGTI-298 was never achieved. The prenylation of K-Ras, on the other hand, was highly resistant to FTI-277 and GGTI-298. Most signi®cantly, treatment of human tumor cell lines with both inhibitors was required for inhibition of K-Ras prenylation. In one cell line, the human lung adenocarcinoma A-549, prenylation of KRas was highly resistant even when co-treated with both inhibitors. Furthermore, soft agar experiments demonstrated that in all the human tumor cell lines tested inhibition of K-Ras prenylation was not necessary for inhibition of anchorage-independent growth. In addition, although GGTI-298 had very little eect on soft agar growth, the combination of FTI-277 and GGTI-298 resulted in signi®cant growth inhibition. Therefore, the results demonstrate that while FTI-277 inhibits N-Ras and H-Ras processing in the human tumor cell lines evaluated, inhibition of K-Ras processing requires both an FTase inhibitor as well as a GGTase I inhibitor, and that inhibition of human tumor growth in soft agar does not require inhibition of oncogenic K-Ras processing.
Introduction
The Ras family of proteins are small guanine nucleotide binding proteins that cycle between their GTP (active) and GDP-bound (inactive) forms to transduce growth and dierentiation signals from receptor tyrosine kinases to the nucleus (McCormick et al., 1993) . Mutations have been identi®ed in all three types of Ras (H-, K-, and N-Ras) proteins in a variety of human tumors, including approximately 90% of pancreatic adenocarcinomas, 50% of colon carcinomas, 20% of lung carcinomas, and 40% of myeloid disorders, with K-Ras mutations occurring most frequently (Barbacid, 1987) . In order for Ras to transduce its normal or oncogenic signal it must be anchored to the plasma membrane, which is accompplished by a series of post-translational modi®cations that increase its hydrophobicity (reviewed in Zhang et al., 1996) . A key step in this process is catalyzed by farnesyltransferase (FTase), an enzyme which transfers farnesyl to the cysteine of the carboxyl-terminal CAAX of Ras, where A is an aliphatic amino acid, and X is serine, methionine, glutamine, or cysteine (Zhang et al., 1996) . A closely related enzyme, geranylgeranyltransferase I (GGTase I), shares the a-subunit of FTase, and attaches the lipid geranylgeranyl to the cysteine of the CAAX box of proteins where X is leucine (Casey et al., 1992; Moomaw et al., 1992) . Because membrane association of Ras is required for its biological function, we and others have designed inhibitors of Ras prenylation as novel anticancer agents (reviewed in Sebti and Hamilton, 1997; Sattler and Tamanoi, 1996; Buss and Marsters, 1996) . We have designed CAAM peptidomimetics such as FTI-276 that are potent and selective inhibitors of FTase over GGTase I in vitro, and that selectively block the processing of farnesylated but not geranylgeranylated proteins in whole cells (Lerner et al., 1995a,b) . We have also designed CAAL peptidomimetics, such as GGTI-287 and GGTI-297, that are selective for GGTase I over FTase (Lerner et al., 1995a; McGuire et al., 1996; Vogt et al., 1996) . Furthermore, we have shown that while H-Ras processing was highly sensitive to FTI-277 and resistant to GGTI-286, KB-Ras was more sensitive to GGTI-286 than FTI-277 (Lerner et al., 1995a ). These results suggested that H-Ras is only farnesylated, while KB-Ras may be both farnesylated and geranylgeranylated in whole cells (Lerner et al., 1995a) . This was consistent with in vitro data that showed that KB-Ras is a substrate for both FTase and GGTase I (James et al., 1995) . Our studies on the relative sensitivities of HRas and KB-Ras processing to the FTase and GGTase I inhibitors were carried out in NIH3T3 cells that were transfected with oncogenically mutated Hand KB-ras oncogenes. While these studies serve as a model to evaluate the potency of CAAX peptidomimetics, they may not be representative of human tumor cells where Ras proteins are naturally expressed. Therefore, the present study was designed to determine the sensitivity of the H-, K-, and N-Ras proteins expressed in human tumor cells to the FTase and GGTase I inhibitors, and to determine whether inhibition of anchorage independent growth in soft agar requires inhibition of oncogenic Ras processing.
Results and discussion
Inhibition of Ras processing in human tumors is dicult to assess with a Pan Ras antibody Although FTase inhibitors were rationally designed with the ultimate goal of developing novel anticancer drugs that block tumor growth by inhibiting Ras processing, at the present time there is little evidence to support this. Furthermore, the Ras mutation status does not predict whether or not a human tumor will be sensitive to FTase inhibitors (Nagasu et al., 1995; Sepp-Lorenzino et al., 1995) . This lack of correlation between sensitivity to FTase inhibitors and Ras mutation status could be due to several reasons. For example, the observed sensitivity to FTase inhibitors of human tumors that do not have Ras mutations could be due to the fact that events responsible for malignant transformation depend on wild type non-mutated Ras or other farnesylated proteins. On the other hand, the resistance of human tumors that express mutated KRas to the FTase inhibitors could be due to their inability to block Ras processing since KB-Ras may be geranylgeranylated when FTase is inhibited (Lerner et al., 1995a; James et al., 1995) . The eects of FTase and GGTase I inhibitors on the processing of Ras proteins expressed in human tumors have not yet been investigated. This has been dicult to do because human tumors appear to express multiple forms of Ras. For example, lysates from the human pancreatic carcinoma Colo357 contain at least two forms of the Ras protein that can be detected by immunoblotting with a pan Ras antibody (Y13-238) which migrated very close to each other on SDS ± PAGE ( Figure 1a , lane 1). On the other hand, these lysates expressed only one form of Rap1A, a small G-protein that is exclusively geranylgeranylated by GGTase I ( Figure  1b , lane 1). When these cells were treated with a range of concentrations of FTI-277 and GGTI-298 as described under`Materials and methods', a third band that migrated slowly appeared while one of the faster migrating bands decreased in intensity when immunoblotted with the pan Ras antibody ( Figure 1a , lanes 2, 3, and 4). The three bands overlapped and it was dicult to determine the relative amounts of processed and unprocessed Ras proteins from these results. Therefore, it was not possible to assess quantitatively the eect of the inhibitors on Ras prenylation using solely a pan Ras antibody. In contrast, the eects of these inhibitors on the processing of Rap1A which is expressed as a single band was easily assessed. Figure  1b (lanes 5 and 6) shows that GGTI-298 at 10 and 15 mM inhibited Rap1A processing by approximately 50%. Higher concentrations of GGTI-298 were too toxic. FTI-277 inhibited the processing of Rap1A at 50 mM but had no eect at 5 and 25 mM (Figure 1b,  lanes 2, 3, 4) . This is consistent with the fact that FTI-277 starts inhibiting GGTase I in whole cells at about 30 mM (Lerner et al., 1995a) . Thus, the results of Figure  1 demonstrate that the inhibitors are capable of eectively reaching their targets in human tumor cell lines, but that it is dicult to assess their eect on Ras prenylation using a pan Ras antibody. 
Human tumor cells express H-, K-and N-Ras

N-Ras is highly sensitive to FTI-277
The data from Figure 2 demonstrated that all human cell lines evaluated, regardless of their tissue of origin, expressed three forms of Ras. We next determined the sensitivity of the individual Ras proteins to FTI-277 and GGTI-298. Cells were treated either with FTI-277 or GGTI-298, alone or in combination. The lysates were isolated and immunoblotted with an antibody speci®c for N-Ras as described under`Materials and methods'. Figure 3 shows that in Panc-1, T24, and A-549, N-Ras prenylation was completely inhibited by concentrations of FTI-277 as low as 5 mM (lane 2), whereas in Colo357 and Calu-1 cells, a small proportion of N-Ras was still processed at 5 mM Inhibition of K-Ras prenylation is highly resistant to FTI-277 and GGTI-298 and requires co-treatment
We then evaluated the sensitivity of K-Ras prenylation to FTI-277 and GGTI-298. Aliquots of the same lysates described in Figure 3 were run on a dierent SDS ± PAGE and immunoblotted with an antibody speci®c to K-Ras. With the exception of T24 cells, the prenylation of K-Ras was resistant to FTI-277 alone even with concentrations as high as 50 mM (Figure 4 , lanes 2, 3, 4). In contrast, K-Ras in T24 cells was partially inhibited by FTI-277 at 25 and 50 mM, but not at 5 mM. While K-Ras prenylation was resistant to GGTI-298 in all of the cell lines (lanes 5 and 6), the combination of FTI-277 and GGTI-298 inhibited KRas prenylation in all but A-549 ( Figure 4 , lanes 7 ± 10). GGTI-298 enhanced the ability of FTI-277 to inhibit K-Ras prenylation in all cell lines except A-549. This interaction is synergistic since FTI-277 (5 mM) and GGTI-298 (10 and 15 mM) alone were ineective, but their combination even at 5 mM/15 mM (FTI-277, GGTI-298) was eective ( Figure 4 , compare lanes 2, 6 and 7). These results strongly suggest that K-Ras in human tumors may be both farnesylated and geranylgeranylated.
Inhibition of H-Ras prenylation is partially sensitive to FTI-277 and GGTI-298
The above results clearly demonstrated that in human tumors, N-Ras prenylation was highly sensitive to FTI-277 whereas K-Ras prenylation was highly resistant to both FTI-277 and GGTI-298. We next determined the sensitivity of H-Ras prenylation to these inhibitors. The panel of the ®ve human tumor cell lines was treated as described in Figure 3 . Aliquots of the same lysates were run on a dierent SDS ± PAGE and immunoblotted using a H-Ras-speci®c antibody. In all cell lines, FTI-277 (5 mM) partially inhibited H-Ras prenylation ( Figure 5 , lane 2). Interestingly, increasing the concentrations of FTI-277 to 25 mM and 50 mM (lanes 3 and 4) did not result in further inhibition of H-Ras prenylation. The prenylation of H-Ras in Colo357 cells and A-549 cells was resistant to GGTI-298, while in Panc-1, T24, and Calu-1 H-Ras prenylation was inhibited partially ( Figure  5 , lanes 5 and 6). Co-treatment with FTI-277 and GGTI-298 did not result in any signi®cant additive eect ( Figure 5 , lanes 7 ± 10). The fact that an apparently fully processed form of H-Ras was still present even at very high concentrations of either FTI-277 or GGTI-298 alone or in combination suggests that under the pressure of these inhibitors, H-Ras may be prenylated by a highly resistant form of either FTase or GGTase I. Alternatively, H-Ras may be processed by a non-prenyltransferase under these conditions. 
Inhibition of soft agar does not require inhibition of oncogenic K-Ras prenylation
We next determined if inhibition of oncogenic Ras prenylation is required for inhibition of anchorageindependent growth in soft agar. The ®ve human tumor cell lines were treated with FTI-277 or GGTI-298 either alone or in combination and their growth in soft agar was evaluated as described under`Materials and methods'. Figure 6 shows that the ability of Colo357 cells to grow on soft agar was signi®cantly compromised by FTI-277. The eect of FTI-277 was apparent at 5 mM and 25 mM, and complete at 50 mM. Table 1 summarizes data obtained from soft agar growth and K-Ras prenylation studies in Panc-1, Colo357, Calu-1, and A-549 cells treated with FTI-277 and GGTI-298. T-24 cells did not grow in soft agar. The eect of GGTI-298 on soft agar growth of cells was minimal. Whereas Calu-1, A-549 and Colo357 were sensitive to FTI-277, Panc-1 was resistant (Table  1) . Co-treatment of FTI-277 (50 mM) and GGTI-298 (15 mM) signi®cantly inhibited soft agar growth of all cells (Table 1) . There was no correlation between inhibition of growth and inhibition of oncogenic KRas processing. For example, FTI-277 (50 mM) blocked growth with no eect on K-Ras prenylation in Colo357 and Calu-1 cells ( Figure 6 and Table 1 ). Furthermore, in A-549 cells, co-treatment with FTI-277 (50 mM) and GGTI-298 (15 mM) blocked growth without aecting oncogenic K-Ras prenylation. Thus, inhibition of the growth of human tumors in soft agar does not require inhibition of the prenylation of oncogenic K-Ras. The work presented in this manuscript clearly demonstrates that the sensitivity to FTase and GGTase I inhibitors of Ras prenylation in human tumors is dierent from that in NIH3T3 cells transfected with various ras oncogenes. In NIH3T3 cells, the prenylation of H-Ras was completely blocked by FTI-277 (1 mM) and was not aected by GGTI-286, an analog of GGTI-298 (Lerner et al., 1995a) . In human tumors, FTI-277 (5 mM) and GGTI-298 (15 mM) inhibited H-Ras prenylation by approximately 50% (Figure 5 ). This suggested that the H-Ras expressed in these human tumors may be alternatively farnesylated and/or geranylgeranylated. In NIH3T3 cells, the prenylation of KB-Ras was inhibited by about 50% with FTI-277 (10 mM), GGTI-286 (3 mM) (Lerner et al., 1995a,b) , and GGTI-298 (3 mM) (unpublished data). In contrast, in four out of ®ve human tumor cell lines evaluated, K-Ras prenylation was resistant to both FTI-277 (up to 50 mM) and GGTI-298 (up to 15 mM), and co-treatment was required for inhibition of its prenylation. This synergistic interaction strongly suggests that K-Ras can be both farnesylated and/or geranylgeranylated in human tumors. In contrast to Hand K-Ras prenylation, the sensitivity of N-Ras prenylation to FTI-277 and GGTI-298 is similar whether N-Ras is expressed naturally in human tumors (Figure 3) or transfected into NIH3T3 cells (unpublished data). In both settings, N-Ras prenyla- tion was blocked by FTI-277 (5 mM). However, in some human tumors such as T24 and Calu-1, GGTI-298 partially inhibited N-Ras prenylation. It is not known why the prenylation sensitivities of the Ras proteins when expressed in their natural environment are dierent from those of the Ras protein when transfected in NIH3T3 cells. It was also surprising that the prenylation of N-Ras was much more sensitive to FTI-277 than was that of H-Ras. A possible explanation for these novel observations is that the prenyltransferases in the human tumors are dierent from those expressed in NIH3T3 cells. Alternatively, the prenylation sensitivity of a Ras protein when overexpressed alone in NIH3T3 cells might be dierent from that of the same Ras protein when co-expressed at normal levels with the other Ras isoforms. Regardless of the reason why prenylation sensitivities are dierent, it is important to emphasize that H-and N-Ras can be inhibited by both FTase and GGTase I inhibitors in human tumors. Most importantly, the prenylation of K-Ras, the most frequently mutated Ras form in human cancers, is highly resistant to both FTI-277 and GGTI-298, and co-treatment is required for its inhibition. This suggests that K-Ras may be both farnesylated and geranylgeranylated, and that the mechanism by which K-Ras resists inhibition involves alternative prenylation by FTase and/or GGTase I. The fact that the prenylation of K-Ras in A-549 cells could not be inhibited suggests that K-Ras may be prenylated by a highly resistant or altogether dierent prenyltransferase.
Furthermore, our results also demonstrate that inhibition of oncogenic K-Ras processing is not required for inhibition of anchorage-independent growth in soft agar. This is consistent with previous reports by Prendergast et al. (1994) , and SeppLorenzino et al. (1995) . In Colo357, A-549 and Calu-1 cells, K-Ras prenylation is inhibited only by cotreatment with FTI-277 and GGTI-298. However, soft agar growth was inhibited by FTI-277 in these cells when K-Ras, the mutated form found in these cells, was not inhibited. The fact that soft agar growth was inhibited in the absence of inhibition of K-Ras prenylation indicates that farnesylated proteins other than K-Ras are targets for FTase inhibitors and these proteins are critical for malignant transformation. This conclusion is further supported by the fact that we have recently shown that tumor growth in nude mice of A-549 and Calu-1 xenografts is greatly inhibited by FTI-276 and GGTI-298 (80% and 60%, respectively) (unpublished data). Therefore, while the FTase and GGTase I inhibitors have been developed to target Ras, there are potentially other proteins which are modi®ed by FTase and GGTase I which may be integral to oncogenic Ras signaling and malignant transformation.
Materials and methods
Synthesis of FTase and GGTase I inhibitors
The inhibitors FTI-277 and GGTI-298 were synthesized and biochemically characterized as described previously (Lerner et al., 1995b; McGuire et al., 1996; Vogt et al., 1996) . Cell culture conditions and reagents
The human pancreatic tumor cell lines Panc-1 and Colo357, which express oncogenic K-Ras with a 12D mutation, were grown in 10% FBS/DMEM supplemented with 1% pen/strep; Calu-1 (a lung adenocarcinoma containing a K-Ras (12C) mutation) and T24 (a bladder carcinoma containing an H-Ras (12V) mutation) were grown in 10% FBS/McCoy's supplemented with 1% pen/ strep; A-549 (a lung adenocarcinoma containing a K-Ras (12S) mutation) was grown in 10% FBS/F12 media supplemented with 1% pen/strep. All cell lines were grown in 10% CO 2 at 378C. Panc-1, T24, Calu-1, and A-549 cell lines were obtained from ATCC (Rockville, Maryland). Colo357 was a kind gift from Dr Adrienne Cox and Dr Channing Der (Chapel Hill, North Carolina). FTase and GGTase I inhibitors were resuspended in 10 mM DTT in DMSO prior to treatment of cells, as described previously (Lerner et al., 1995a,b) .
Ras and Rap1A processing assays
Panc-1, Colo357, T24, A-549, and Calu-1 cell lines were seeded on day 0 in 100 mm dishes in the appropriate medium. On day 1, when cells were approximately 50% con¯uent, cells were refed with medium containing various concentrations of FTI-277 and/or GGTI-298 (either alone or in combination) or vehicle (10 mM DTT in DMSO). Cells were refed on day 2 with the appropriate medium and inhibitors. On day 3, cells were washed with ice cold PBS and lysed in lysis buer containing 50 mM HEPES, pH 7.5, 10 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM MgCl 2 , 1 mM EGTA, 25 mg/ml leupeptin, 2 mM phenylmethylsulfonyl¯uoride, 2 mM sodium orthovanadate, 10 mg/ml soybean trypsin inhibitor, and 10 mg/ml aprotinin. Lysates were cleared (14 000 r.p.m., 48C, 15 min), and equal amounts of protein were separated by 12.5% SDS ± PAGE, transferred to nitrocellulose, and immunoblotted with either a pan Ras antibody derived from a rat (Y13-238, ATCC), a N-Ras speci®c antibody derived from a rabbit (SC-519, Santa Cruz Biotechnology, Santa Cruz, California), a K-Ras speci®c antibody derived from a mouse (SC-030, Santa Cruz Biotechnology), an H-Ras speci®c antibody derived from a mouse (LA069, Quality Biotech, Camden, New Jersey), or a Rap1A speci®c antibody derived from a rabbit (SC-65, Santa Cruz Biotechnology). Antibody reactions were visualized using either peroxidase-conjugated goat anti-rat IgG (GIBCO, Gaithersburg, Maryland) (for Y13-238), peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania) (for Rap1A and N-Ras) or peroxidase-conjugated donkey anti-mouse IgG (Jackson Immuno Research Laboratories Inc., West Grove, Pennsylvania) (for H-Ras or K-Ras), and an enhanced chemiluminesence detection system (ECL, Amersham Corp.).
Anchorage independent growth assays
For soft agar growth assays, the cell lines were seeded at various cell densities in triplicate (a range of 3500 cells per well to 50 000 cells per well depending on the cell line) in 12-well culture dishes in 0.35% agar over a 0.7% agar layer. Various concentrations of FTI-277 and/or GGTI-298 or vehicle (10 mM DTT in DMSO) were included in the 0.35% agar layer of cells. Cultures were fed and treated with drug or vehicle twice weekly until colonies grew to a suitable size for observation (colony growth rates were approximately 10 days for the PANC-1 and Colo357 cells, 3 weeks for A-549 and 6 weeks for Calu-1. T24 cells did not form colonies even after 3 months). Colonies were photographed after incubation with 1 mg/ml MTT in the respective cell growth media for 3 h to overnight. The growth of colonies in the presence of inhibitor was compared to the control colonies treated with vehicle.
Note in proof: Very recently Whyte et al. (1997) reported that K-Ras and N-Ras became geranylgeranylated when cells are treated with FTase inhibitors. Similar results with K-Ras were obtaind by Rowell et al. (1997) .
Abbreviations
FTase, farnesyltransferase; GGTase I, geranylgeranyltranferase I; CAAX, tetrapeptides where C=cysteine, A=aliphatic amino acid, X=any amino acid; SDS ± PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; MVA, mevalonic acid; FPP, farnesylpyrophosphate; GGPP, geranylgernaylpyrophosphate; PBS, phosphate buered saline; DTT, dithiothreitol; DMSO, dimethylsulfoxide; MTT, 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide.
